scholarly journals P8‐63: Impact of the lung immune prognostic index (LIPI) in limited disease small cell lung cancer patients treated with chemoradiotherapy

Respirology ◽  
2021 ◽  
Vol 26 (S3) ◽  
pp. 312-312
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Prognostic Index ◽  
Small Cell ◽  
Small Cell Lung ◽  
Limited Disease ◽  
Lung Cancer Patients

Pretreatment lung immune prognostic index as biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumab

Immunotherapy ◽  
2021 ◽  
Author(s):  
Antonello Veccia ◽  
Vincenzo Sforza ◽  
Emanuela Vattemi ◽  
Alessandro Inno ◽  
Stefania Kinspergher ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Prognostic Index ◽  
Progression Free Survival ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
C Statistic

Background: To investigate the role of pretreatment lung immune prognostic index (LIPI) as biomarker in PD-L1 ≥50% non-small-cell lung cancer patients receiving pembrolizumab. Patients & methods: We retrospectively identified 117 patients, divided into 3 prognostic groups according to LIPI score. For each patient, we evaluated 1-year overall survival (OS) and progression-free survival rate. C-statistic and survival receiver operating characteristic curves were used to study discrimination of LIPI. Results: After a median follow-up of 11.7 months, 1-year OS rate was 60.1%, 35.3% and 28.6%, while 1-year progression-free survival rate was 39.1%, 20.6% and 14.3% in good, intermediate and poor LIPI groups, respectively (p < 0.001). The c-statistic and area under the curve of LIPI were 0.63 and 0.662 for OS and 1-year OS, respectively. Conclusions: Higher LIPI score is related to worse survival in advanced non-small-cell lung cancer patients treated with first-line pembrolizumab. However, based on c-statistic and area under the curve, LIPI does not represent a good prognostic survival model.

scholarly journals Hypofractionated conformal radiotherapy in combination with chemotherapy in limited disease small cell lung cancer patients

2014 ◽  
Vol 82 (2) ◽  
pp. 105-115 ◽  
Author(s):  
Joanna Socha ◽  
Agnieszka Guzowska ◽  
Dobromira Tyc-Szczepaniak ◽  
Aleksandra Szczęsna ◽  
Lucyna Kępka
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Conformal Radiotherapy ◽  
Small Cell ◽  
Small Cell Lung ◽  
Limited Disease ◽  
Lung Cancer Patients

Timing of Failure in Limited Disease (Stage I-III) Small-Cell Lung Cancer Patients Treated with Chemoradiotherapy: A Retrospective Analysis

2013 ◽  
Vol 99 (6) ◽  
pp. 656-660 ◽  
Author(s):  
Farkhad Manapov ◽  
Sabine Klöcking ◽  
Maximilian Niyazi ◽  
Feras Oskan ◽  
Olivier M Niemöller ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Retrospective Analysis ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Disease Stage ◽  
Small Cell Lung ◽  
Limited Disease ◽  
Lung Cancer Patients

scholarly journals Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy

2019 ◽  
Vol 8 (6) ◽  
pp. 1078-1085 ◽  
Author(s):  
Juan Ruiz-Bañobre ◽  
María C. Areses-Manrique ◽  
Joaquín Mosquera-Martínez ◽  
Alexandra Cortegoso ◽  
Francisco J. Afonso-Afonso ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Prognostic Index ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document